Table 2 Correlation of HRD status and clinical parameters of EOC patients in the training group
From: Whole exome sequencing-based homologous recombination deficiency test for epithelial ovarian cancer
HRD positive status | Platinum response | Recurrence | Death | ||||
|---|---|---|---|---|---|---|---|
Total | Sensitive | Resistant | No | Yes | No | Yes | |
40 | 23 | 17 | 9 | 31 | 19 | 21 | |
WES-based scarHRD test | Â | Â | Â | Â | Â | ||
 Negative | 9 | 1(4.3%) | 8(47.1%) | 0(0%) | 9(29%) | 3(15.8%) | 6(28.6%) |
 Positive | 31 | 22(95.7%) | 9(52.9%) | 9(100%) | 22(71%) | 16(84.2%) | 15(71.4%) |
 p value* |  |  | 0.002 |  | 0.090 |  | 0.457 |
Myriad MyChoice® CDx HRD test |  |  |  |  |  | ||
 Negative | 9 | 1(4.3%) | 8(47.1%) | 0(0%) | 9 (29%) | 4(21.1%) | 5(23.8%) |
 Positive | 31 | 22(95.7%) | 9(52.9%) | 9(100%) | 22(71%) | 15(78.9%) | 16(76.2%) |
 p value* |  |  | 0.002 |  | 0.090 |  | 1.000 |